Farmacología, aspectos farmacocinéticos e interacciones de atazanavir
Pharmacology, pharmacokinetic features and interactions of atazanavir
Luis F. López-Cortés
Autor para correspondencia
lflopez@telefonica.net
Correspondencia: Dr. L.F. López-Cortés. Avda. Manuel Siurot, s/n. 41013 Sevilla. España.
Correspondencia: Dr. L.F. López-Cortés. Avda. Manuel Siurot, s/n. 41013 Sevilla. España.
Servicio de Enfermedades Infecciosas. Hospital Universitario Virgen del Rocío. Sevilla. España
Leído
4248
Vecesse ha leído el artículo
1157
Total PDF
3091
Total HTML
Compartir estadísticas
array:23 [ "pii" => "S0213005X08766138" "issn" => "0213005X" "doi" => "10.1016/S0213-005X(08)76613-8" "estado" => "S300" "fechaPublicacion" => "2008-12-01" "aid" => "76613" "copyright" => "Elsevier España S.L.. Todos los derechos reservados" "copyrightAnyo" => "2008" "documento" => "article" "crossmark" => 0 "subdocumento" => "fla" "cita" => "Enferm Infecc Microbiol Clin. 2008;26 Supl 17:2-8" "abierto" => array:3 [ "ES" => false "ES2" => false "LATM" => false ] "gratuito" => false "lecturas" => array:2 [ "total" => 2648 "formatos" => array:3 [ "EPUB" => 8 "HTML" => 2037 "PDF" => 603 ] ] "itemSiguiente" => array:18 [ "pii" => "S0213005X0876614X" "issn" => "0213005X" "doi" => "10.1016/S0213-005X(08)76614-X" "estado" => "S300" "fechaPublicacion" => "2008-12-01" "aid" => "76614" "copyright" => "Elsevier España S.L." "documento" => "article" "crossmark" => 0 "subdocumento" => "fla" "cita" => "Enferm Infecc Microbiol Clin. 2008;26 Supl 17:9-13" "abierto" => array:3 [ "ES" => false "ES2" => false "LATM" => false ] "gratuito" => false "lecturas" => array:2 [ "total" => 1790 "formatos" => array:3 [ "EPUB" => 9 "HTML" => 1011 "PDF" => 770 ] ] "es" => array:10 [ "idiomaDefecto" => true "titulo" => "Eficacia de atazanavir en pacientes <span class="elsevierStyleItalic">naïve</span>" "tienePdf" => "es" "tieneTextoCompleto" => 0 "tieneResumen" => array:2 [ 0 => "es" 1 => "en" ] "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "9" "paginaFinal" => "13" ] ] "titulosAlternativos" => array:1 [ "en" => array:1 [ "titulo" => "Efficacy of atazanavir in treatment-naive patients" ] ] "contieneResumen" => array:2 [ "es" => true "en" => true ] "contienePdf" => array:1 [ "es" => true ] "autores" => array:1 [ 0 => array:2 [ "autoresLista" => "Santiago Moreno, Beatriz Hernández, Fernando Dronda" "autores" => array:3 [ 0 => array:2 [ "nombre" => "Santiago" "apellidos" => "Moreno" ] 1 => array:2 [ "nombre" => "Beatriz" "apellidos" => "Hernández" ] 2 => array:2 [ "nombre" => "Fernando" "apellidos" => "Dronda" ] ] ] ] ] "idiomaDefecto" => "es" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S0213005X0876614X?idApp=UINPBA00004N" "url" => "/0213005X/0000002600000S17/v1_201305090109/S0213005X0876614X/v1_201305090109/es/main.assets" ] "itemAnterior" => array:18 [ "pii" => "S0213005X08766126" "issn" => "0213005X" "doi" => "10.1016/S0213-005X(08)76612-6" "estado" => "S300" "fechaPublicacion" => "2008-12-01" "aid" => "76612" "copyright" => "Elsevier España S.L." "documento" => "simple-article" "crossmark" => 0 "subdocumento" => "mis" "cita" => "Enferm Infecc Microbiol Clin. 2008;26 Supl 17:1" "abierto" => array:3 [ "ES" => false "ES2" => false "LATM" => false ] "gratuito" => false "lecturas" => array:2 [ "total" => 1390 "formatos" => array:3 [ "EPUB" => 8 "HTML" => 923 "PDF" => 459 ] ] "es" => array:7 [ "idiomaDefecto" => true "titulo" => "Introducción: la utilidad de atazanavir en el tratamiento de los pacientes infectados por el virus de la inmunodeficiencia humana" "tienePdf" => "es" "tieneTextoCompleto" => 0 "paginas" => array:1 [ 0 => array:1 [ "paginaInicial" => "1" ] ] "contienePdf" => array:1 [ "es" => true ] "autores" => array:1 [ 0 => array:2 [ "autoresLista" => "Antonio Rivero" "autores" => array:1 [ 0 => array:2 [ "nombre" => "Antonio" "apellidos" => "Rivero" ] ] ] ] ] "idiomaDefecto" => "es" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S0213005X08766126?idApp=UINPBA00004N" "url" => "/0213005X/0000002600000S17/v1_201305090109/S0213005X08766126/v1_201305090109/es/main.assets" ] "es" => array:12 [ "idiomaDefecto" => true "titulo" => "Farmacología, aspectos farmacocinéticos e interacciones de atazanavir" "tieneTextoCompleto" => 0 "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "2" "paginaFinal" => "8" ] ] "autores" => array:1 [ 0 => array:4 [ "autoresLista" => "Luis F. López-Cortés" "autores" => array:1 [ 0 => array:4 [ "nombre" => "Luis F." "apellidos" => "López-Cortés" "email" => array:1 [ 0 => "lflopez@telefonica.net" ] "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">¿</span>" "identificador" => "cor1" ] ] ] ] "afiliaciones" => array:1 [ 0 => array:1 [ "entidad" => "Servicio de Enfermedades Infecciosas. Hospital Universitario Virgen del Rocío. Sevilla. España" ] ] "correspondencia" => array:1 [ 0 => array:3 [ "identificador" => "cor1" "etiqueta" => "⁎" "correspondencia" => "Correspondencia: Dr. L.F. López-Cortés. Avda. Manuel Siurot, s/n. 41013 Sevilla. España." ] ] ] ] "titulosAlternativos" => array:1 [ "en" => array:1 [ "titulo" => "Pharmacology, pharmacokinetic features and interactions of atazanavir" ] ] "pdfFichero" => "main.pdf" "tienePdf" => true "PalabrasClave" => array:2 [ "es" => array:1 [ 0 => array:4 [ "clase" => "keyword" "titulo" => "Palabras clave" "identificador" => "xpalclavsec137551" "palabras" => array:3 [ 0 => "Atazanavir" 1 => "Farmacología" 2 => "Farmacocinética" ] ] ] "en" => array:1 [ 0 => array:4 [ "clase" => "keyword" "titulo" => "Key words" "identificador" => "xpalclavsec137550" "palabras" => array:3 [ 0 => "Atazanavir" 1 => "Pharmacology" 2 => "Pharmacokinetics" ] ] ] ] "tieneResumen" => true "resumen" => array:2 [ "es" => array:1 [ "resumen" => "<p class="elsevierStyleSimplePara elsevierViewall">Atazanavir (ATV) es un inhibidor de la proteasa (IP) del virus de la inmunodeficiencia humana (VIH) con alta actividad in vitro frente al VIH-1, que muestra una actividad aditiva en presencia de otros antirretrovirales y una actividad sinérgica con otros IP. Su absorción por vía oral es superior al 68%, alcanzándose la concentración máxima (C<span class="elsevierStyleInf">máx</span>) aproximadamente 2-3 h después de su administración. Su absorción está relacionada con el pH gástrico, recomendándose su administración tras las comidas. La farmacocinética de ATV no es lineal; es decir, sus concentraciones plasmáticas (C<span class="elsevierStyleInf">p</span>) no aumentan en proporción con las dosis. ATV se une aproximadamente en un 86% a las proteínas plasmáticas. Su penetración en el líquido cefalorraquídeo, el semen o las secreciones genitales es variable, pero en general inferior al 10-20%. Su paso a través de la placenta, medido como la media de los cocientes entre las C<span class="elsevierStyleInf">p</span> en sangre de cordón umbilical respecto a las maternas, es de 0,13. El ATV es metabolizado mediante oxidación por las enzimas del citocromo P450, eliminándose con posterioridad por vía biliar en forma libre o glucuronidada (80%) y por la orina. Asimismo, es un inhibidor competitivo débil de la CYP3A4 y un fuerte inhibidor de la uridina difosfatoglucuronosiltransferasa 1A1, que es la causa de la frecuente hiperbilirrubinemia tras su administración y de sus interacciones farmacológicas.</p>" ] "en" => array:1 [ "resumen" => "<p class="elsevierStyleSimplePara elsevierViewall">Atazanavir (ATV) is an HIV protease inhibitor (IP) with a high <span class="elsevierStyleItalic">in vitro</span> activity against HIV-1, that demonstrates a high additive activity in the presence of other antiretrovirals and a synergic activity with other PI. Oral absorption is greater than 68%, maximum concentration (C<span class="elsevierStyleInf">max</span>) being reached approximately 2 to 3 h after its administration. Its absorption is dependent on gastric pH, its administration being recommended after meals. The pharmacokinetics (PK) of ATV are non-linear; that is to say, its plasma concentrations (C<span class="elsevierStyleInf">p</span>) do not increase in proportion to the dose. ATV is approximately 86% bound to plasma proteins. Its entry into the cerebrospinal fluid, semen or genital secretions varies but is generally less than 10-20%. Its passage across the placenta, measured as the mean of the ratios between the C<span class="elsevierStyleInf">p</span> in umbilical cord and maternal blood, is 0.13. ATV is metabolised by oxidation by cytochrome P450 enzymes, subsequently being eliminated by the bile duct in the free or glucuronide form (80%) and by the urine. ATV is a weak competitive inhibitor of CYP3A4 and a strong inhibitor of uridine diphosphate-glucuronosyltransferase 1A1, which is the cause of the frequent high plasma bilirubin after its administration and of its pharmacological interactions.</p>" ] ] "bibliografia" => array:2 [ "titulo" => "Bibliografía" "seccion" => array:1 [ 0 => array:1 [ "bibliografiaReferencia" => array:64 [ 0 => array:3 [ "identificador" => "bib1" "etiqueta" => "1." "referencia" => array:1 [ 0 => array:1 [ "referenciaCompleta" => "Reyataz. Ficha técnica del producto, 2008. European Medicines Agency. Disponible en: <a class="elsevierStyleInterRef" href="http://www.emea.europa.eu/humandocs/Humans/EPAR/reyataz/reyataz.htm">http://www.emea.europa.eu/humandocs/Humans/EPAR/reyataz/reyataz.htm</a>." ] ] ] 1 => array:3 [ "identificador" => "bib2" "etiqueta" => "2." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "BMS-232632, a highly potent human immunodeficiency virus protease inhibitor that can be used in combination with other available antiretroviral agents" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "B.S. Robinson" 1 => "K.A. Riccardi" 2 => "Y.F. Gong" 3 => "Q. Guo" 4 => "D.A. Stock" 5 => "W.S. Blair" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:6 [ "tituloSerie" => "Antimicrob Agents Chemother" "fecha" => "2000" "volumen" => "44" "paginaInicial" => "2093" "paginaFinal" => "2099" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/10898681" "web" => "Medline" ] ] ] ] ] ] ] ] 2 => array:3 [ "identificador" => "bib3" "etiqueta" => "3." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Synergistic inhibition of protease-inhibitor-resistant HIV type 1 by saquinavir in combination with atazanavir or lopinavir" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "E. Dam" 1 => "S. Lebel-Binay" 2 => "S. Rochas" 3 => "L. Thibaut" 4 => "J.L. Faudon" 5 => "C.M. Thomas" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:6 [ "tituloSerie" => "Antivir Ther" "fecha" => "2007" "volumen" => "12" "paginaInicial" => "371" "paginaFinal" => "380" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/17591027" "web" => "Medline" ] ] ] ] ] ] ] ] 3 => array:3 [ "identificador" => "bib4" "etiqueta" => "4." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "CASTLE study: Pharmacokinetics and inhibitory quotient of atazanavir/ritonavir 300/100 mg once daily compared to lopinavir/ritonavir 400/100 mg twice daily, each in combination with fixed dose tenofovir-emtricitabine once daily, are supportive of 48 week efficacy and safety in HIV-1 infected, treatment naive subjects" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "L. Zhu" 1 => "M. Liao" 2 => "H. Chil" 3 => "H. Sevinsky" 4 => "T. Eley" 5 => "Y. Wang" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "LibroEditado" => array:2 [ "titulo" => "New Orleans: 9<span class="elsevierStyleSup">th</span> International Workshop on Clinical Pharmacology of HIV Therapy" "serieFecha" => "2008" ] ] ] ] ] ] 4 => array:3 [ "identificador" => "bib5" "etiqueta" => "5." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Hollow-fiber unit evaluation of a new human immunodeficiency virus type 1 protease inhibitor, BMS-232632, for determination of the linked pharmacodynamic variable" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "G.L. Drusano" 1 => "J.A. Bilello" 2 => "S.L. Preston" 3 => "E. O’Mara" 4 => "S. Kaul" 5 => "S. Schnittman" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1086/319281" "Revista" => array:6 [ "tituloSerie" => "J Infect Dis" "fecha" => "2001" "volumen" => "183" "paginaInicial" => "1126" "paginaFinal" => "1129" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/11237841" "web" => "Medline" ] ] ] ] ] ] ] ] 5 => array:3 [ "identificador" => "bib6" "etiqueta" => "6." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "BMS-232632: single oral dose safety and pharmacokinetic study in healthy volunteers" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:6 [ 0 => "M. O’Mara" 1 => "J. Smith" 2 => "S.J. Olsen" 3 => "T. Tanner" 4 => "A.E. Schuster" 5 => "S. Kaul" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "LibroEditado" => array:3 [ "titulo" => "38<span class="elsevierStyleSup">th</span> Interscience Conference on Antimi crobial Agents and Chemotherapy" "conferencia" => "Sep 24-27; San Diego" "serieFecha" => "1998" ] ] ] ] ] ] 6 => array:3 [ "identificador" => "bib7" "etiqueta" => "7." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Multiple-dose pharmacokinetics of atazanavir in healthy subjects: a summary of food effect and drug interaction studies" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:3 [ 0 => "D. Randall" 1 => "S. Agarwala" 2 => "V. Mummanemi" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "LibroEditado" => array:3 [ "titulo" => "42nd Interscience Conference on Antimicrobial Agents and Chemotherapy" "conferencia" => "San Diego" "serieFecha" => "2002" ] ] ] ] ] ] 7 => array:3 [ "identificador" => "bib8" "etiqueta" => "8." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Population pharmacokinetics of atazanavir in patients with human immunodeficiency virus infection" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "S. Colombo" 1 => "T. Buclin" 2 => "M. Cavassini" 3 => "L.A. Décosterd" 4 => "A. Telenti" 5 => "J. Biollaz" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:5 [ "tituloSerie" => "Atimicrob Agents Chemother" "fecha" => "2006" "volumen" => "50" "paginaInicial" => "3801" "paginaFinal" => "3808" ] ] ] ] ] ] 8 => array:3 [ "identificador" => "bib9" "etiqueta" => "9." "referencia" => array:1 [ 0 => array:1 [ "referenciaCompleta" => "Randall D, Agarwala S, Mummanemi V, et al. Tissue compartment concentrations of atazanavir in cerebrospinal fluid, semial fluid and plasma in HIV+ subjects. 42nd Abstract n.° H-1711." ] ] ] 9 => array:3 [ "identificador" => "bib10" "etiqueta" => "10." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Penetration of atazanavir in seminal plasma of men infected with human immunodeficiency virus type 1" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:6 [ 0 => "E. Van Leeuwen" 1 => "R. Ter Heine" 2 => "F. Van der Veen" 3 => "S. Repping" 4 => "J.H. Beijnen" 5 => "J.M. Prins" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1128/AAC.00774-06" "Revista" => array:6 [ "tituloSerie" => "Antimicrob Agents Chemother" "fecha" => "2007" "volumen" => "51" "paginaInicial" => "335" "paginaFinal" => "337" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/17074793" "web" => "Medline" ] ] ] ] ] ] ] ] 10 => array:3 [ "identificador" => "bib11" "etiqueta" => "11." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Antiretroviral drug exposure in the female genital tract: implications for oral pre- and post-exposure prophylaxis" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "J.B. Dumond" 1 => "R.F. Yeh" 2 => "K.B. Patterson" 3 => "A.H. Corbett" 4 => "B.H. Jung" 5 => "N.L. Rezk" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1097/QAD.0b013e328270385a" "Revista" => array:6 [ "tituloSerie" => "AIDS" "fecha" => "2007" "volumen" => "21" "paginaInicial" => "1899" "paginaFinal" => "1907" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/17721097" "web" => "Medline" ] ] ] ] ] ] ] ] 11 => array:3 [ "identificador" => "bib12" "etiqueta" => "12." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Atazanavir plus low-dose ritonavir in pregnancy: pharmacokinetics and placental transfer" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "D. Ripamonti" 1 => "D. Cattaneo" 2 => "F. Maggiolo" 3 => "M. Airoldi" 4 => "L. Frigerio" 5 => "P. Bertuletti" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:5 [ "tituloSerie" => "AIDS" "fecha" => "2007" "volumen" => "21" "paginaInicial" => "2409" "paginaFinal" => "2415" ] ] ] ] ] ] 12 => array:3 [ "identificador" => "bib13" "etiqueta" => "13." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Clinical pharmacokinetics and summary of efficacy and tolerability of atazanavir" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:4 [ 0 => "C. Le Tiec" 1 => "A. Barrail" 2 => "C. Goujard" 3 => "A.M. Taburet" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:5 [ "tituloSerie" => "Clin Pharmacokinet" "fecha" => "2005" "volumen" => "44" "paginaInicial" => "1035" "paginaFinal" => "1050" ] ] ] ] ] ] 13 => array:3 [ "identificador" => "bib14" "etiqueta" => "14." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Influence of atazanavir 200 mg on the intracellular and plasma pharmacokinetics of saquinavir and ritonavir 1600/100 mg administered once daily in HIV-infected patients" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "J. Ford" 1 => "M. Boffito" 2 => "D. Maitland" 3 => "A. Hill" 4 => "D. Back" 5 => "S. Khoo" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1093/jac/dkl379" "Revista" => array:6 [ "tituloSerie" => "J Antimicrob Chemother" "fecha" => "2006" "volumen" => "58" "paginaInicial" => "1009" "paginaFinal" => "1016" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/16984898" "web" => "Medline" ] ] ] ] ] ] ] ] 14 => array:3 [ "identificador" => "bib15" "etiqueta" => "15." "referencia" => array:1 [ 0 => array:1 [ "referenciaCompleta" => "Reyataz. Scientific discussion. European Medicines Agency. Disponible en: <a class="elsevierStyleInterRef" href="http://www.emea.europa.eu/humandocs/PDFs/EPAR/reyataz/586503en6.pdf">http://www.emea.europa.eu/humandocs/PDFs/EPAR/reyataz/586503en6.pdf</a>" ] ] ] 15 => array:3 [ "identificador" => "bib16" "etiqueta" => "16." "referencia" => array:1 [ 0 => array:1 [ "referenciaCompleta" => "Reyataz. Full Prescribing Information. US Food and Drug Administration. 2008. Disponible en: <a class="elsevierStyleInterRef" href="http://www.fda.gov/cder/foi/label/2008/021567s015lbl.pdf">http://www.fda.gov/cder/foi/label/2008/021567s015lbl.pdf</a>" ] ] ] 16 => array:3 [ "identificador" => "bib17" "etiqueta" => "17." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "BMS-232632: a prospective study of age and gender effects on the single-dose pharmacokinetics in healthy volunteers" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:5 [ 0 => "E. O’Mara" 1 => "D. Randall" 2 => "R. Stoltz" 3 => "M. Geraldes" 4 => "V. Mummaneni" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "LibroEditado" => array:3 [ "titulo" => "1st International AIDS Society Conference" "conferencia" => "Buenos Aires" "serieFecha" => "2001" ] ] ] ] ] ] 17 => array:3 [ "identificador" => "bib18" "etiqueta" => "18." "referencia" => array:1 [ 0 => array:1 [ "referenciaCompleta" => "Von Hentig N, Babacan E, Lennemann T, Knecht G, Carlebach A, Harder S, et al. The steady-state pharmacokinetics of atazanavir/ritonavir in HIV-1- infected adult outpatients is not affected by gender-related co-factors. J Antimicrob Chemother. 2008; Advance Access published on May 13, 2008." ] ] ] 18 => array:3 [ "identificador" => "bib19" "etiqueta" => "19." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "BMS-232632: a preliminary pharmacokinetic and pharmacodynamic evaluation of BMS-232632 in a protease inhibitor-naive HIV+ population [abstract P9]" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "E. O’Mara" 1 => "P. Piliero" 2 => "G. Drusano" 3 => "V. Mummaneni" 4 => "S. Preston" 5 => "A. Schuster" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:5 [ "tituloSerie" => "AIDS" "fecha" => "2000" "volumen" => "14" "numero" => "Suppl. 4" "paginaInicial" => "S19" ] ] ] ] ] ] 19 => array:3 [ "identificador" => "bib20" "etiqueta" => "20." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Therapeutic drug monitoring of atazanavir: surveillance of pharmacotherapy in the clinic" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:4 [ 0 => "J.E. Ray" 1 => "D. Marriott" 2 => "M.T. Bloch" 3 => "A.J. McLachlan" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1111/j.1365-2125.2005.02413.x" "Revista" => array:6 [ "tituloSerie" => "Br J Clin Pharmacol" "fecha" => "2005" "volumen" => "60" "paginaInicial" => "291" "paginaFinal" => "299" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/16120068" "web" => "Medline" ] ] ] ] ] ] ] ] 20 => array:3 [ "identificador" => "bib21" "etiqueta" => "21." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Atazanavir plasma concentrations vary significantly between patients and correlate with increased serum bilirubin concentrations" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:3 [ 0 => "D.E. Smith" 1 => "S. Jeganathan" 2 => "J. Ray" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1310/0KX0-H9VH-99EE-5D0L" "Revista" => array:6 [ "tituloSerie" => "HIV Clin Trials" "fecha" => "2006" "volumen" => "7" "paginaInicial" => "34" "paginaFinal" => "38" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/16632461" "web" => "Medline" ] ] ] ] ] ] ] ] 21 => array:3 [ "identificador" => "bib22" "etiqueta" => "22." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Monitoring atazanavir concentrations with boosted or unboosted regimens in HIV-infected patients in routine clinical practice" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "J. Moltó" 1 => "J.R. Santos" 2 => "M. Valle" 3 => "C. Miranda" 4 => "J. Miranda" 5 => "A. Blanco" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1097/FTD.0b013e31815704c1" "Revista" => array:6 [ "tituloSerie" => "Ther Drug Monit" "fecha" => "2007" "volumen" => "29" "paginaInicial" => "648" "paginaFinal" => "651" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/17898658" "web" => "Medline" ] ] ] ] ] ] ] ] 22 => array:3 [ "identificador" => "bib23" "etiqueta" => "23." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Atazanavir (ATV) plasma concentrations in HIV-infected patients treated with 400 mg ATV or ritonavir boosted ATV (300/100 mg) qd in clinical practice" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:3 [ 0 => "J.M. Poirier" 1 => "J. Guiard-Schmid" 2 => "J. Meynard" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "LibroEditado" => array:3 [ "titulo" => "7th International Workshop on Clinical Pharmacology of HIV Therapy" "conferencia" => "Lisbon" "serieFecha" => "2006" ] ] ] ] ] ] 23 => array:3 [ "identificador" => "bib24" "etiqueta" => "24." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Assessment of Pharmacokinetic/Pharmacodynamic Relationships through 48 Weeks from a Study in HIV+, ART-naive Subjects Receiving Antiretroviral Regimens Containing Atazanavir 400 mg or Atazanavir/Ritonavir 300/100 mg Once Daily" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "R. Bertz" 1 => "Y. Wang" 2 => "L. Mahnke" 3 => "A. Persson" 4 => "E. Chung" 5 => "M. Mathew" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "LibroEditado" => array:3 [ "titulo" => "14th Conference on Retroviruses and Opportunistic Infections" "conferencia" => "Los Angeles" "serieFecha" => "2007" ] ] ] ] ] ] 24 => array:3 [ "identificador" => "bib25" "etiqueta" => "25." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Atazanavir trough plasma concentration monitoring in a cohort of HIV-1-positive individuals receiving highly active antiretroviral therapy" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "A. Winston" 1 => "M. Bloch" 2 => "A. Carr" 3 => "J. Amin" 4 => "P.W. Mallon" 5 => "J. Ray" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1093/jac/dki235" "Revista" => array:6 [ "tituloSerie" => "J Antimicrob Chemother" "fecha" => "2005" "volumen" => "56" "paginaInicial" => "380" "paginaFinal" => "387" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/15996972" "web" => "Medline" ] ] ] ] ] ] ] ] 25 => array:3 [ "identificador" => "bib26" "etiqueta" => "26." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Therapeutic drug monitoring of the HIV protease inhibitor atazanavir in clinical practice" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "R.M. Cleijsen" 1 => "M.E. Van de Ende" 2 => "F.P. Kroon" 3 => "F.V. Lunel" 4 => "P.P. Koopmans" 5 => "L. Gras" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1093/jac/dkm298" "Revista" => array:6 [ "tituloSerie" => "J Antimicrob Chemother" "fecha" => "2007" "volumen" => "60" "paginaInicial" => "897" "paginaFinal" => "900" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/17704117" "web" => "Medline" ] ] ] ] ] ] ] ] 26 => array:3 [ "identificador" => "bib27" "etiqueta" => "27." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "A pilot study evaluating plasma and intracellular pharmacokinetics (PK) of switching from atazanavir (ATV) 400mg QD to ATV 200 mg BID in HIV+ patients" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:3 [ 0 => "S. Bonora" 1 => "A. D’Avolio" 2 => "C. Tettoni" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "LibroEditado" => array:3 [ "titulo" => "9th International Workshop on Clinical Pharmacology of HIV Therapy" "conferencia" => "New Orleans" "serieFecha" => "2008" ] ] ] ] ] ] 27 => array:3 [ "identificador" => "bib28" "etiqueta" => "28." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Pharmacokinetic enhancement of protease inhibitor therapy" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:4 [ 0 => "J.R. King" 1 => "H. Wynn" 2 => "R. Brundage" 3 => "E.P. Acosta" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.2165/00003088-200443050-00003" "Revista" => array:6 [ "tituloSerie" => "Clin Pharmacokinet" "fecha" => "2004" "volumen" => "43" "paginaInicial" => "291" "paginaFinal" => "310" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/15080763" "web" => "Medline" ] ] ] ] ] ] ] ] 28 => array:3 [ "identificador" => "bib29" "etiqueta" => "29." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Steady-State Pharmacokinetic (PK) Interaction Study of Atazanavir (ATV) with Ritonavir (RTV) in Healthy Subjects" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:6 [ 0 => "S. Agarwala" 1 => "R. Russo" 2 => "V. Mummaneni" 3 => "D. Randall" 4 => "M. Geraldes" 5 => "E. O’Mara" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "LibroEditado" => array:3 [ "titulo" => "42nd Interscience Conference on Antimicrobial Agents and Chemotherapy" "conferencia" => "San Diego" "serieFecha" => "2002" ] ] ] ] ] ] 29 => array:3 [ "identificador" => "bib30" "etiqueta" => "30." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Interactions between atazanavir-ritonavir and tenofovir in heavily pretreated human immunodeficiency virus-infected patients" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "A.M. Taburet" 1 => "C. Piketty" 2 => "C. Chazallon" 3 => "I. Vincent" 4 => "L. Gérard" 5 => "V. Calvez" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1128/AAC.48.6.2091-2096.2004" "Revista" => array:6 [ "tituloSerie" => "Antimicrob Agents Chemother" "fecha" => "2004" "volumen" => "48" "paginaInicial" => "2091" "paginaFinal" => "2096" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/15155205" "web" => "Medline" ] ] ] ] ] ] ] ] 30 => array:3 [ "identificador" => "bib31" "etiqueta" => "31." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Virological responses to atazanavir-ritonavir-based regimens: resistance-substitutions score and pharmacokinetic parameters (Reyaphar study)" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "I. Pellegrin" 1 => "D. Breilh" 2 => "J.M. Ragnaud" 3 => "S. Boucher" 4 => "D. Neau" 5 => "H. Fleury" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:6 [ "tituloSerie" => "Antivir Ther" "fecha" => "2006" "volumen" => "11" "paginaInicial" => "421" "paginaFinal" => "429" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/16856615" "web" => "Medline" ] ] ] ] ] ] ] ] 31 => array:3 [ "identificador" => "bib32" "etiqueta" => "32." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Genetic factors influencing atazanavir plasma concentrations and the risk of severe hyperbilirubinemia" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "S. Rodríguez-Nóvoa" 1 => "L. Martín-Carbonero" 2 => "P. Barreiro" 3 => "G. González-Pardo" 4 => "I. Jiménez- Nácher" 5 => "J. González-Lahoz" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1097/QAD.0b013e328011d7c1" "Revista" => array:6 [ "tituloSerie" => "AIDS" "fecha" => "2007" "volumen" => "21" "paginaInicial" => "41" "paginaFinal" => "46" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/17148966" "web" => "Medline" ] ] ] ] ] ] ] ] 32 => array:3 [ "identificador" => "bib33" "etiqueta" => "33." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Atazanavir and lopinavir with ritonavir alone or in combination: analysis of pharmacokinetic interaction and predictors of drug exposure" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "S. Di Giambenedetto" 1 => "A. De Luca" 2 => "P. Villani" 3 => "A. Bacarelli" 4 => "E. Ragazzoni" 5 => "M. Regazzi" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1111/j.1468-1293.2008.00555.x" "Revista" => array:6 [ "tituloSerie" => "HIV Med" "fecha" => "2008" "volumen" => "9" "paginaInicial" => "239" "paginaFinal" => "245" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/18366448" "web" => "Medline" ] ] ] ] ] ] ] ] 33 => array:3 [ "identificador" => "bib34" "etiqueta" => "34." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Atazanavir trough is associated with efficacy and safety: definition of therapeutic range" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "D. Gonzalez de Requena" 1 => "S. Bonora" 2 => "F. Canta" 3 => "R. Marrone" 4 => "A. D’Avolio" 5 => "M. Sciandra" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "LibroEditado" => array:3 [ "titulo" => "12th Conference on Retroviruses and Opportunistic Infections" "conferencia" => "Boston" "serieFecha" => "2005" ] ] ] ] ] ] 34 => array:3 [ "identificador" => "bib35" "etiqueta" => "35." "referencia" => array:1 [ 0 => array:1 [ "referenciaCompleta" => "Optimizing TDM in HIV clinical care. 2003. Disponible en: <a class="elsevierStyleInterRef" href="http://www.hivpharmacology.com/">http://www.hivpharmacology.com</a>." ] ] ] 35 => array:3 [ "identificador" => "bib36" "etiqueta" => "36." "referencia" => array:1 [ 0 => array:1 [ "referenciaCompleta" => "Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services [accedido Ene 08]. Disponible en: <a class="elsevierStyleInterRef" href="http://www.aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf">http://www.aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf</a>" ] ] ] 36 => array:3 [ "identificador" => "bib37" "etiqueta" => "37." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Pharmacokinetics of Atazanavir in severely renally impaired subjects including those on hemodialysis" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "S. Agarwala" 1 => "T. Eley" 2 => "M. Child" 3 => "A. Persson" 4 => "D. Filoramo" 5 => "X. Xu" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "LibroEditado" => array:3 [ "titulo" => "8th International Workshop on Clinical Pharmacology of HIV Therapy" "conferencia" => "Budapest. Hungary" "serieFecha" => "2007" ] ] ] ] ] ] 37 => array:3 [ "identificador" => "bib38" "etiqueta" => "38." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Influence of liver fibrosis stage on plasma levels of antiretroviral drugs in HIV-infected patients with chronic hepatitis C" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "P. Barreiro" 1 => "S. Rodríguez-Novoa" 2 => "P. Labarga" 3 => "A. Ruiz" 4 => "I. Jiménez-Nácher" 5 => "L. Martín-Carbonero" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1086/512086" "Revista" => array:6 [ "tituloSerie" => "J Infect Dis" "fecha" => "2007" "volumen" => "195" "paginaInicial" => "973" "paginaFinal" => "979" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/17330787" "web" => "Medline" ] ] ] ] ] ] ] ] 38 => array:3 [ "identificador" => "bib39" "etiqueta" => "39." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Atazanavir Use in Pregnancy: a report of 33 cases" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "M. Natha" 1 => "P. Hay" 2 => "G. Taylor" 3 => "C. Wood" 4 => "L. Sarner" 5 => "L. Cunningham" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "LibroEditado" => array:3 [ "titulo" => "14th Conference on Retroviruses and Opportunistic Infections" "conferencia" => "Los Angeles" "serieFecha" => "2007" ] ] ] ] ] ] 39 => array:3 [ "identificador" => "bib40" "etiqueta" => "40." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Atazanavir plus low-dose ritonavir in pregnancy: pharmacokinetics and placental transfer" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "D. Ripamonti" 1 => "D. Cattaneo" 2 => "F. Maggiolo" 3 => "M. Airoldi" 4 => "L. Frigerio" 5 => "P. Bertuletti" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:5 [ "tituloSerie" => "AIDS" "fecha" => "2007" "volumen" => "21" "paginaInicial" => "2409" "paginaFinal" => "2415" ] ] ] ] ] ] 40 => array:3 [ "identificador" => "bib41" "etiqueta" => "41." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Pharmacokinetic interaction between atazanavir and omeprazole in healthy subjects" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:3 [ 0 => "S. Agarwala" 1 => "K. Gray" 2 => "T. Elay" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "LibroEditado" => array:3 [ "titulo" => "3rd Internation al AIDS Society Conference on HIV Pathogenesis and Treatmen" "conferencia" => "Rio de Janeiro" "serieFecha" => "2005" ] ] ] ] ] ] 41 => array:3 [ "identificador" => "bib42" "etiqueta" => "42." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Inhibition of atazanavir oral absorption by lansoprazole gastric acid suppression in healthy volunteers" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "D.L. Tomilo" 1 => "P.F. Smith" 2 => "A.B. Ogundele" 3 => "R. Difrancesco" 4 => "C.S. Berenson" 5 => "E. Eberhardt" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1592/phco.26.3.341" "Revista" => array:6 [ "tituloSerie" => "Pharmacotherapy" "fecha" => "2006" "volumen" => "26" "paginaInicial" => "341" "paginaFinal" => "346" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/16503713" "web" => "Medline" ] ] ] ] ] ] ] ] 42 => array:3 [ "identificador" => "bib43" "etiqueta" => "43." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Steadystate pharmacokinetics of once-daily fosamprenavir/ritonavir and atazanavir/ ritonavir alone and in combination with 20 mg omeprazole in healthy volunteers" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:6 [ 0 => "A.D. Luber" 1 => "R. Brower" 2 => "D. Kim" 3 => "R. Silverman" 4 => "C.A. Peloquin" 5 => "I. Frank" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:5 [ "tituloSerie" => "HIV Med" "fecha" => "2007" "volumen" => "8" "paginaInicial" => "457" "paginaFinal" => "464" ] ] ] ] ] ] 43 => array:3 [ "identificador" => "bib44" "etiqueta" => "44." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Effects of esomeprazole on the pharmacokinetics of atazanavir and fosamprenavir in a patient with human immunodeficiency virus infection" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:4 [ 0 => "J.J. Kiser" 1 => "K.A. Lichtenstein" 2 => "P.L. Anderson" 3 => "C.V. Fletcher" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1592/phco.26.4.511" "Revista" => array:6 [ "tituloSerie" => "Pharmacotherapy" "fecha" => "2006" "volumen" => "26" "paginaInicial" => "511" "paginaFinal" => "514" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/16553510" "web" => "Medline" ] ] ] ] ] ] ] ] 44 => array:3 [ "identificador" => "bib45" "etiqueta" => "45." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Effect of famotidine 20 and 40mg dosing regimens on the bioavailability of atazanavir with ritonavir in combination with tenofovir in healthy subjects" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:3 [ 0 => "S. Agarwala" 1 => "A. Persson" 2 => "M. Eley" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "LibroEditado" => array:3 [ "titulo" => "14th Conference on Retrovirus and Opportunistic Infections" "conferencia" => "Los Angeles" "serieFecha" => "2007" ] ] ] ] ] ] 45 => array:3 [ "identificador" => "bib46" "etiqueta" => "46." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Proton pump inhibitors do not reduce atazanavir concentrations in HIV-infected patients treated with ritonavir-boosted atazanavir" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "J.B. Guiard-Schmid" 1 => "J.M. Poirier" 2 => "P. Bonnard" 3 => "J.L. Meynard" 4 => "L. Slama" 5 => "T. Lukiana" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:5 [ "tituloSerie" => "AIDS" "fecha" => "2005" "volumen" => "19" "paginaInicial" => "1937" "paginaFinal" => "1938" ] ] ] ] ] ] 46 => array:3 [ "identificador" => "bib47" "etiqueta" => "47." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Clinical outcomes associated with concomitant use of atazanavir and proton pump inhibitors" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:2 [ 0 => "E.G. Sahloff" 1 => "J.M. Duggan" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1345/aph.1H217" "Revista" => array:6 [ "tituloSerie" => "Ann Pharmacother" "fecha" => "2006" "volumen" => "40" "paginaInicial" => "1731" "paginaFinal" => "1736" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/16968825" "web" => "Medline" ] ] ] ] ] ] ] ] 47 => array:3 [ "identificador" => "bib48" "etiqueta" => "48." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Ritonavir-boosted atazanavir may be efficacious in HIV-infected patients concurrently receiving omeprazole" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:2 [ 0 => "K.M. Chan-Tack" 1 => "A. Edozien" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1086/503305" "Revista" => array:5 [ "tituloSerie" => "Clin Infect Dis" "fecha" => "2006" "volumen" => "42" "paginaInicial" => "1344" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/16586398" "web" => "Medline" ] ] ] ] ] ] ] ] 48 => array:3 [ "identificador" => "bib49" "etiqueta" => "49." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Proton pump inhibitor therapy in atazanavir-treated patients: contraindicated?" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:4 [ 0 => "K.J. Furtek" 1 => "N.F. Crum" 2 => "P.E. Olson" 3 => "M.R. Wallace" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1097/01.qai.0000192002.23400.6e" "Revista" => array:6 [ "tituloSerie" => "J Acquir Immune Defic Syndr" "fecha" => "2006" "volumen" => "41" "paginaInicial" => "394" "paginaFinal" => "396" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/16540945" "web" => "Medline" ] ] ] ] ] ] ] ] 49 => array:3 [ "identificador" => "bib50" "etiqueta" => "50." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Effect of rifampin on steady-state pharmacokinetics of atazanavir with ritonavir in healthy volunteers" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:6 [ 0 => "D.M. Burger" 1 => "S. Agarwala" 2 => "M. Child" 3 => "A. Been-Tiktak" 4 => "Y. Wang" 5 => "R. Bertz" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1128/AAC.00461-06" "Revista" => array:6 [ "tituloSerie" => "Antimicrob Agents Chemother" "fecha" => "2006" "volumen" => "50" "paginaInicial" => "3336" "paginaFinal" => "3342" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/17005814" "web" => "Medline" ] ] ] ] ] ] ] ] 50 => array:3 [ "identificador" => "bib51" "etiqueta" => "51." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Pharmacokinetic interaction between rifampicin and ritonavir-boosted atazanavir in HIV-infected patients" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "J. Mallolas" 1 => "M. Sarasa" 2 => "M. Nomdedeu" 3 => "A. Soriano" 4 => "Y. López-Púa" 5 => "J.L. Blanco" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1111/j.1468-1293.2007.00442.x" "Revista" => array:6 [ "tituloSerie" => "HIV Med" "fecha" => "2007" "volumen" => "8" "paginaInicial" => "131" "paginaFinal" => "134" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/17352770" "web" => "Medline" ] ] ] ] ] ] ] ] 51 => array:3 [ "identificador" => "bib52" "etiqueta" => "52." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Effect of concomitantly administered rifampin on the pharmacokinetics and safety of atazanavir administered twice daily" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "E.P. Acosta" 1 => "M.A. Kendall" 2 => "J.G. Gerber" 3 => "B. Alston-Smith" 4 => "S.L. Koletar" 5 => "A.R. Zolopa" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1128/AAC.00341-07" "Revista" => array:6 [ "tituloSerie" => "Antimicrob Agents Chemother" "fecha" => "2007" "volumen" => "51" "paginaInicial" => "3104" "paginaFinal" => "3110" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/17576825" "web" => "Medline" ] ] ] ] ] ] ] ] 52 => array:3 [ "identificador" => "bib53" "etiqueta" => "53." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Pharmacokinetic effect of rifabutin on atazanavir with and without ritonavir in healthy subjects" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:6 [ 0 => "S. Agarwala" 1 => "V. Mummaneni" 2 => "D. Randall" 3 => "M. Geraldes" 4 => "R. Stoltz" 5 => "E. O’Mara" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "LibroEditado" => array:3 [ "titulo" => "9th Conference on Retroviruses and Opportunistic Infections" "conferencia" => "Seattle" "serieFecha" => "2002" ] ] ] ] ] ] 53 => array:3 [ "identificador" => "bib54" "etiqueta" => "54." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Evaluation of steady-state interaction between atazanavir and efavirenz" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:3 [ 0 => "S. Preston" 1 => "P. Piliero" 2 => "E. O’Mara" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "LibroEditado" => array:3 [ "titulo" => "9th Conference on Retroviruses and Opportunistic Infections" "conferencia" => "Seattle" "serieFecha" => "2002" ] ] ] ] ] ] 54 => array:3 [ "identificador" => "bib55" "etiqueta" => "55." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Influence of tenofovir, nevirapine and efavirenz on ritonavir-boosted atazanavir pharmacokinetics in HIV-infected patients" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "E. Dailly" 1 => "O. Tribut" 2 => "P. Tattevin" 3 => "C. Arvieux" 4 => "P. Perré" 5 => "F. Raffi" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1007/s00228-006-0122-2" "Revista" => array:6 [ "tituloSerie" => "Eur J Clin Pharmacol" "fecha" => "2006" "volumen" => "62" "paginaInicial" => "523" "paginaFinal" => "526" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/16763827" "web" => "Medline" ] ] ] ] ] ] ] ] 55 => array:3 [ "identificador" => "bib56" "etiqueta" => "56." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Pharmacokinetics of TMC125, with atazanavir and atazanavir/ritonavir" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:3 [ 0 => "M. Schöller-Gyüre" 1 => "B. Woodfall" 2 => "T. De Marez" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "LibroEditado" => array:3 [ "titulo" => "46<span class="elsevierStyleSup">th</span>Interscience Conference on Antimicrobial Agents and Chemotherapy" "conferencia" => "San Francisco" "serieFecha" => "2006" ] ] ] ] ] ] 56 => array:3 [ "identificador" => "bib57" "etiqueta" => "57." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Pharmacokinetic Evaluation of the Combination of Atazanavir, Enteric Coated Didanosine, and Tenofovir Disoproxil Fumarate for a Once-Daily Antiretroviral Regimen" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "S. Kaul" 1 => "K. Bassi" 2 => "B. Damle" 3 => "J. Xie" 4 => "J. Gale" 5 => "B. Kearne" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "LibroEditado" => array:3 [ "titulo" => "43<span class="elsevierStyleSup">th</span> Interscience Conference on Antimicrobial Agents and Chemotherapy" "conferencia" => "Chicago" "serieFecha" => "2003" ] ] ] ] ] ] 57 => array:3 [ "identificador" => "bib58" "etiqueta" => "58." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Interactions between atazanavir-ritonavir and tenofovir in heavily pretreated human immunodeficiency virus-infected patients" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "A.M. Taburet" 1 => "C. Piketty" 2 => "C. Chazallon" 3 => "I. Vincent" 4 => "L. Gérard" 5 => "V. Calvez" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1128/AAC.48.6.2091-2096.2004" "Revista" => array:6 [ "tituloSerie" => "Antimicrob Agents Chemother" "fecha" => "2004" "volumen" => "48" "paginaInicial" => "2091" "paginaFinal" => "2096" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/15155205" "web" => "Medline" ] ] ] ] ] ] ] ] 58 => array:3 [ "identificador" => "bib59" "etiqueta" => "59." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Tenofovir comedication does not impair the steady-state pharmacokinetics of ritonavir-boosted atazanavir in HIV-1-infected adults" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "N. Von Hentig" 1 => "B. Dauer" 2 => "A. Haberl" 3 => "S. Klauke" 4 => "T. Lutz" 5 => "S. Staszewski" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1007/s00228-007-0344-y" "Revista" => array:6 [ "tituloSerie" => "Eur J Clin Pharmacol" "fecha" => "2007" "volumen" => "63" "paginaInicial" => "935" "paginaFinal" => "940" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/17665183" "web" => "Medline" ] ] ] ] ] ] ] ] 59 => array:3 [ "identificador" => "bib60" "etiqueta" => "60." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Lack of an effect of atazanavir on steady-state pharmacokinetics of methadone in patients chronically treated for opiate addiction" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "G. Friedland" 1 => "L. Andrews" 2 => "T. Schreibman" 3 => "S. Agarwala" 4 => "L. Daley" 5 => "M. Child" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:6 [ "tituloSerie" => "AIDS" "fecha" => "2005" "volumen" => "19" "paginaInicial" => "1635" "paginaFinal" => "1641" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/16184033" "web" => "Medline" ] ] ] ] ] ] ] ] 60 => array:3 [ "identificador" => "bib61" "etiqueta" => "61." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Pharmacokinetics of saquinavir, atazanavir, and ritonavir in a twice-daily boosted double-protease inhibitor regimen" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "N. Von Hentig" 1 => "A. Müller" 2 => "C. Rottmann" 3 => "T. Wolf" 4 => "T. Lutz" 5 => "S. Klauke" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1128/AAC.00854-06" "Revista" => array:6 [ "tituloSerie" => "Antimicrob Agents Chemother" "fecha" => "2007" "volumen" => "51" "paginaInicial" => "1431" "paginaFinal" => "1439" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/17296738" "web" => "Medline" ] ] ] ] ] ] ] ] 61 => array:3 [ "identificador" => "bib62" "etiqueta" => "62." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Atazanavir and lopinavir/ritonavir: pharmacokinetics, safety and efficacy of a promising double-boosted protease inhibitor regimen" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "E. Ribera" 1 => "C. Azuaje" 2 => "R.M. Lopez" 3 => "M. Diaz" 4 => "M. Feijoo" 5 => "L. Pou" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1097/01.aids.0000226953.56976.ad" "Revista" => array:6 [ "tituloSerie" => "AIDS" "fecha" => "2006" "volumen" => "20" "paginaInicial" => "1131" "paginaFinal" => "1139" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/16691064" "web" => "Medline" ] ] ] ] ] ] ] ] 62 => array:3 [ "identificador" => "bib63" "etiqueta" => "63." "referencia" => array:1 [ 0 => array:1 [ "referenciaCompleta" => "Raltegravir. Ficha técnica del producto. 2008. European Medicines Agency. Disponible en: <a class="elsevierStyleInterRef" href="http://www.emea.europa.eu/humandocs/Humans/EPAR/isentress/%20isentress.htm">http://www.emea.europa.eu/humandocs/Humans/EPAR/isentress/ isentress.htm</a>" ] ] ] 63 => array:3 [ "identificador" => "bib64" "etiqueta" => "64." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Effects of CYP3A4 inhibitors on the pharmacokinetics of maraviroc in healthy volunteers" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:5 [ 0 => "S. Abel" 1 => "D. Russell" 2 => "R.J. Taylor-Worth" 3 => "C.E. Ridgway" 4 => "G.J. Muirhead" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1111/j.1365-2125.2008.03133.x" "Revista" => array:7 [ "tituloSerie" => "Br J Clin Pharmacol" "fecha" => "2008" "volumen" => "65" "numero" => "Suppl 1" "paginaInicial" => "27" "paginaFinal" => "37" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/18333863" "web" => "Medline" ] ] ] ] ] ] ] ] ] ] ] ] ] "idiomaDefecto" => "es" "url" => "/0213005X/0000002600000S17/v1_201305090109/S0213005X08766138/v1_201305090109/es/main.assets" "Apartado" => null "PDF" => "https://static.elsevier.es/multimedia/0213005X/0000002600000S17/v1_201305090109/S0213005X08766138/v1_201305090109/es/main.pdf?idApp=UINPBA00004N&text.app=https://www.elsevier.es/" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S0213005X08766138?idApp=UINPBA00004N" ]
| año/Mes | Html | Total | |
|---|---|---|---|
| 2024 Noviembre | 1 | 0 | 1 |
| 2024 Octubre | 12 | 3 | 15 |
| 2024 Septiembre | 24 | 6 | 30 |
| 2024 Agosto | 17 | 3 | 20 |
| 2024 Julio | 12 | 2 | 14 |
| 2024 Junio | 10 | 6 | 16 |
| 2024 Mayo | 12 | 5 | 17 |
| 2024 Abril | 25 | 5 | 30 |
| 2024 Marzo | 16 | 9 | 25 |
| 2024 Febrero | 16 | 5 | 21 |
| 2024 Enero | 21 | 5 | 26 |
| 2023 Diciembre | 21 | 6 | 27 |
| 2023 Noviembre | 19 | 11 | 30 |
| 2023 Octubre | 24 | 24 | 48 |
| 2023 Septiembre | 9 | 7 | 16 |
| 2023 Agosto | 9 | 5 | 14 |
| 2023 Julio | 8 | 5 | 13 |
| 2023 Junio | 24 | 8 | 32 |
| 2023 Mayo | 27 | 0 | 27 |
| 2023 Abril | 31 | 3 | 34 |
| 2023 Marzo | 11 | 7 | 18 |
| 2023 Febrero | 9 | 0 | 9 |
| 2023 Enero | 5 | 5 | 10 |
| 2022 Diciembre | 9 | 10 | 19 |
| 2022 Noviembre | 7 | 4 | 11 |
| 2022 Octubre | 47 | 4 | 51 |
| 2022 Septiembre | 39 | 14 | 53 |
| 2022 Agosto | 17 | 7 | 24 |
| 2022 Julio | 13 | 7 | 20 |
| 2022 Junio | 9 | 8 | 17 |
| 2022 Mayo | 6 | 13 | 19 |
| 2022 Abril | 10 | 8 | 18 |
| 2022 Marzo | 12 | 4 | 16 |
| 2022 Febrero | 8 | 7 | 15 |
| 2022 Enero | 10 | 15 | 25 |
| 2021 Diciembre | 8 | 11 | 19 |
| 2021 Noviembre | 12 | 10 | 22 |
| 2021 Octubre | 16 | 17 | 33 |
| 2021 Septiembre | 11 | 10 | 21 |
| 2021 Agosto | 10 | 11 | 21 |
| 2021 Julio | 16 | 9 | 25 |
| 2021 Junio | 10 | 10 | 20 |
| 2021 Mayo | 18 | 12 | 30 |
| 2021 Abril | 50 | 31 | 81 |
| 2021 Marzo | 66 | 92 | 158 |
| 2021 Febrero | 25 | 7 | 32 |
| 2021 Enero | 29 | 8 | 37 |
| 2020 Diciembre | 48 | 16 | 64 |
| 2020 Noviembre | 19 | 5 | 24 |
| 2020 Octubre | 14 | 4 | 18 |
| 2020 Septiembre | 22 | 11 | 33 |
| 2020 Agosto | 23 | 17 | 40 |
| 2020 Julio | 18 | 15 | 33 |
| 2020 Junio | 15 | 5 | 20 |
| 2020 Mayo | 26 | 5 | 31 |
| 2020 Abril | 17 | 7 | 24 |
| 2020 Marzo | 20 | 7 | 27 |
| 2020 Febrero | 25 | 7 | 32 |
| 2020 Enero | 15 | 4 | 19 |
| 2019 Diciembre | 26 | 13 | 39 |
| 2019 Noviembre | 24 | 15 | 39 |
| 2019 Octubre | 34 | 14 | 48 |
| 2019 Septiembre | 33 | 20 | 53 |
| 2019 Agosto | 7 | 9 | 16 |
| 2019 Julio | 12 | 11 | 23 |
| 2019 Junio | 47 | 20 | 67 |
| 2019 Mayo | 118 | 18 | 136 |
| 2019 Abril | 59 | 26 | 85 |
| 2019 Marzo | 10 | 8 | 18 |
| 2019 Febrero | 11 | 29 | 40 |
| 2019 Enero | 10 | 8 | 18 |
| 2018 Diciembre | 10 | 5 | 15 |
| 2018 Noviembre | 11 | 11 | 22 |
| 2018 Octubre | 16 | 12 | 28 |
| 2018 Septiembre | 6 | 4 | 10 |
| 2018 Agosto | 9 | 16 | 25 |
| 2018 Julio | 5 | 3 | 8 |
| 2018 Junio | 6 | 13 | 19 |
| 2018 Mayo | 2 | 9 | 11 |
| 2018 Abril | 5 | 3 | 8 |
| 2018 Marzo | 6 | 2 | 8 |
| 2018 Febrero | 0 | 1 | 1 |
| 2018 Enero | 1 | 2 | 3 |
| 2017 Diciembre | 8 | 3 | 11 |
| 2017 Noviembre | 5 | 5 | 10 |
| 2017 Octubre | 10 | 2 | 12 |
| 2017 Septiembre | 7 | 2 | 9 |
| 2017 Agosto | 15 | 1 | 16 |
| 2017 Julio | 12 | 1 | 13 |
| 2017 Junio | 10 | 7 | 17 |
| 2017 Mayo | 18 | 14 | 32 |
| 2017 Abril | 10 | 15 | 25 |
| 2017 Marzo | 12 | 23 | 35 |
| 2017 Febrero | 15 | 1 | 16 |
| 2017 Enero | 10 | 4 | 14 |
| 2016 Diciembre | 11 | 3 | 14 |
| 2016 Noviembre | 8 | 3 | 11 |
| 2016 Octubre | 16 | 5 | 21 |
| 2016 Septiembre | 11 | 1 | 12 |
| 2016 Agosto | 9 | 1 | 10 |
| 2016 Julio | 10 | 2 | 12 |
| 2016 Junio | 31 | 9 | 40 |
| 2016 Mayo | 36 | 12 | 48 |
| 2016 Abril | 22 | 16 | 38 |
| 2016 Marzo | 17 | 10 | 27 |
| 2016 Febrero | 21 | 20 | 41 |
| 2016 Enero | 18 | 18 | 36 |
| 2015 Diciembre | 19 | 19 | 38 |
| 2015 Noviembre | 25 | 14 | 39 |
| 2015 Octubre | 28 | 15 | 43 |
| 2015 Septiembre | 13 | 13 | 26 |
| 2015 Agosto | 38 | 3 | 41 |
| 2015 Julio | 37 | 3 | 40 |
| 2015 Junio | 11 | 4 | 15 |
| 2015 Mayo | 19 | 6 | 25 |
| 2015 Abril | 19 | 6 | 25 |
| 2015 Marzo | 14 | 3 | 17 |
| 2015 Febrero | 16 | 7 | 23 |
| 2015 Enero | 23 | 2 | 25 |
| 2014 Diciembre | 22 | 5 | 27 |
| 2014 Noviembre | 18 | 3 | 21 |
| 2014 Octubre | 41 | 2 | 43 |
| 2014 Septiembre | 30 | 3 | 33 |
| 2014 Agosto | 19 | 1 | 20 |
| 2014 Julio | 28 | 2 | 30 |
| 2014 Junio | 16 | 3 | 19 |
| 2014 Mayo | 20 | 1 | 21 |
| 2014 Abril | 15 | 2 | 17 |
| 2014 Marzo | 29 | 2 | 31 |
| 2014 Febrero | 18 | 1 | 19 |
| 2014 Enero | 24 | 2 | 26 |
| 2013 Diciembre | 21 | 3 | 24 |
| 2013 Noviembre | 34 | 2 | 36 |
| 2013 Octubre | 37 | 4 | 41 |
| 2013 Septiembre | 16 | 6 | 22 |
| 2013 Agosto | 22 | 6 | 28 |
| 2013 Julio | 17 | 2 | 19 |
| 2008 Diciembre | 509 | 0 | 509 |
Mostrar todo
